Sustainalytics’ Controversies Research identifies companies involved in incidents and events that may negatively impact stakeholders, the environment or the company’s operations. Controversies ...
FDA-Approved Sickle Cell Therapies From Bluebird Bio And Vertex Join Medicaid Innovation Program CMS launches an outcomes-based model to expand access to FDA-approved gene therapies for sickle ...
Short interest in bluebird bio Inc (NASDAQ:BLUE) increased during the last reporting period, rising from 2.41M to 2.42M. This put 26.93% of the company's publicly available shares short.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback